{"id":46704,"date":"2026-04-09T21:47:45","date_gmt":"2026-04-09T21:47:45","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/46704\/"},"modified":"2026-04-09T21:47:45","modified_gmt":"2026-04-09T21:47:45","slug":"hnl-lab-medicine-and-roche-diagnostics-form-preferred-partnership","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/46704\/","title":{"rendered":"HNL Lab Medicine and Roche Diagnostics Form Preferred Partnership"},"content":{"rendered":"<p class=\"has-text-align-left\"><a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/digital-pathology\/hnl-lab-medicine-ibex-ai-prostate-cancer-diagnostics\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\" class=\"text-editor-link-class\">HNL Lab Medicine<\/a> announced a preferred partnership with <a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/clinical-chemistry\/clinical-chemistry-analyzers\/fda-clears-roche-cobas-c703-ise-neo-analytical-units\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">Roch<\/a><a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/clinical-chemistry\/clinical-chemistry-analyzers\/fda-clears-roche-cobas-c703-ise-neo-analytical-units\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\" class=\"text-editor-link-class\">e<\/a><a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/clinical-chemistry\/clinical-chemistry-analyzers\/fda-clears-roche-cobas-c703-ise-neo-analytical-units\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\"> Diagnostics<\/a> to focus on innovation, operational excellence, and advancing patient care through technology, according to a press release from the company.<\/p>\n<p class=\"has-text-align-left\">The partnership is intended to enhance laboratory performance by improving the speed and accuracy of diagnostic results. By utilizing Roche\u2019s solutions, HNL Lab Medicine aims to provide clinicians with the insights necessary to deliver better patient outcomes.<\/p>\n<p class=\"has-text-align-left\">Roche Diagnostics produces medical tests and digital solutions designed to assist healthcare professionals in clinical decision-making. Its laboratory solutions are built to help facilities maximize staff efficiency, reduce turnaround times for critical tests, and standardize operations while supporting sustainability goals.<\/p>\n<p class=\"has-text-align-left\">HNL Lab Medicine processes approximately 5.6 million specimens each year, delivering more than 63 million laboratory results through its network of more than 50 patient service centers and 31 acute care laboratories, according to the company. Currently, 99% of the organization\u2019s in-house test results are delivered within 24 hours.<\/p>\n<p class=\"has-text-align-left\">\u201cThe lab industry continues to encounter many new and often unpredictable challenges, making it important to have strong and reliable partnerships,\u201d says Warren W. Erdmann, chief operating officer of HNL Lab Medicine, in a release. \u201cThe essence behind our preferred partnership recognition is to foster long-term alignment with partners we trust, enabling us to address these challenges together.\u201d<\/p>\n<p class=\"has-text-align-left\"><a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/global-in-vitro-diagnostics-market-forecast-2030\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\" class=\"text-editor-link-class\">In vitro diagnostics<\/a>\u2014tests performed using blood, tissue, or urine\u2014supported by Roche\u2019s solutions are involved in an estimated 70% of healthcare decisions throughout a patient\u2019s journey.<\/p>\n<p class=\"has-text-align-left\">\u201cBy working closely with our valued partners, we can find mutually beneficial solutions, offer flexibility when needed, and collaborate to achieve win-win successes,\u201d says Erdmann, in a release.<\/p>\n<p class=\"has-text-align-left\">HNL Lab Medicine is a multi-regional, full-service medical laboratory providing testing to physician offices, hospitals, long-term care facilities, and employers throughout Pennsylvania. The organization employs more than 2,000 people, including over 100 pathologists and scientific directors.<\/p>\n<p class=\"has-text-align-left\">ID <a class=\"text-editor-link-class\" href=\"https:\/\/www.dreamstime.com\/royalty-free-stock-photo-business-agreement-image286585\" rel=\"nofollow noopener\" target=\"_blank\">286585<\/a> \u00a9 <a class=\"text-editor-link-class\" href=\"https:\/\/www.dreamstime.com\/rjmiz_info\" rel=\"nofollow noopener\" target=\"_blank\">Anthony Furgison<\/a> | <a class=\"text-editor-link-class\" href=\"http:\/\/Dreamstime.com\" rel=\"nofollow noopener\" target=\"_blank\">Dreamstime.com<\/a><\/p>\n<p class=\"has-text-align-left\">Related Reading:<\/p>\n<p class=\"has-text-align-left\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"HNL Lab Medicine announced a preferred partnership with Roche Diagnostics to focus on innovation, operational excellence, and advancing&hellip;\n","protected":false},"author":2,"featured_media":46705,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[9023,19366,1176,26108,3493,27027,3516,27028,27029,7021,134,2057],"class_list":["post-46704","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-clinical-laboratory","tag-diagnostic-accuracy","tag-diagnostics","tag-hnl-lab-medicine","tag-in-vitro-diagnostics","tag-laboratory-efficiency","tag-laboratory-operations","tag-laboratory-partnerships","tag-laboratory-technology","tag-patient-care","tag-roche","tag-roche-diagnostics"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116376950804408158","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=46704"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46704\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/46705"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=46704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=46704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=46704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}